Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
REGULATORY
MHLW Proposes Creating Legal Provision on RWD-Only Drug Submissions
The Ministry of Health, Labor and Welfare (MHLW) has proposed stipulating in the Pharmaceuticals and Medical Devices (PMD) Act that it is possible to file for regulatory approval of drugs based on real-world clinical data alone. The proposal was made…
To read the full story
Related Article
- Japan Citizens’ Group Opposes RWD-Only Drug Submissions
December 16, 2024
- Japan Wants to Spur Regulatory Use of RWD, but Still Puts Weight on RCTs
July 10, 2024
- MHLW Panel to Draw Up Report by Year-End towards Amendment of PMD Act
February 13, 2024
REGULATORY
- NCC President Nakagama to Lead AMED from April
March 26, 2025
- Pariet’s Nonprescription Versions Approved 6 Years after Discussions Start
March 25, 2025
- AMED President Mishima Hints at Resignation
March 25, 2025
- FPMAJ Prods Drastic Review of Fiscal Framework before Honebuto 2025
March 25, 2025
- Difficult to “Visualize” Distribution, Production Costs in NHI Prices: Minister
March 25, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…